SCHEMBL4150602

SCHEMBL4150602

NC(=O)c1ccc(Oc2cccc(OCc3ccccc3)c2)s1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 3/20 0.51
SPHK1 Q9NYA1 1/20 0.51
NR4A2 P43354 2/20 0.50
SIRT2 Q8IXJ6 1/20 0.48
MAOB P27338 3/20 0.48
PARP10 Q53GL7 1/20 0.48
F10 P00742 2/20 0.47
F9 P00740 1/20 0.47
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SMPD1 P17405 1/20 0.46
MEN1 O00255 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
SRD5A2 P31213 1/20 0.45
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159497 0.82 PARP10 (0.51) NR4A2SIRT2MAOBPARP10F10
SCHEMBL4144009 0.81 PARP10 (0.50) SIRT2PARP10KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4161369 0.80 CYP3A4 (0.42) PARP10F10
SCHEMBL1680585 0.78 MAOB (0.50) SPHK2SPHK1NR4A2MAOBCYP4F2
SCHEMBL4155387 0.76 ICAM1 (0.54) PARP10F10KMT2ASMN1; SMN2KDM4E
SCHEMBL4148474 0.76 CDK1 (0.54) MAOBPARP10F10KMT2A
SCHEMBL1680567 0.74 MAOB (0.49) NR4A2MAOBKMT2ASMPD1MEN1
SCHEMBL28237963 0.74 MAOB (0.72) NR4A2MAOBKMT2ASMPD1MEN1
SCHEMBL1387246 0.74 NR4A2 (0.77) SPHK2NR4A2MAOBPARP10F10
SCHEMBL5249598 0.74 KMT2A (0.65) SPHK2SPHK1NR4A2SIRT2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD SPHK2 2713/4885SPHK1 1588/4885NR4A2 2336/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 SPHK2 3832/4885SPHK1 2668/4885NR4A2 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.